Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN(R) in Combination ... MarketWatch (press release) The trial is designed to enroll a total of 100 patients in North America, who will be randomized to one of two treatment arms: ZEVALIN + rituximab, and MGd, or ZEVALIN + rituximab. The treatment period will be 10-12 days, followed by 12-week safety ... Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination ... |
